JP2014522868A - 精製タンパク質 - Google Patents

精製タンパク質 Download PDF

Info

Publication number
JP2014522868A
JP2014522868A JP2014523080A JP2014523080A JP2014522868A JP 2014522868 A JP2014522868 A JP 2014522868A JP 2014523080 A JP2014523080 A JP 2014523080A JP 2014523080 A JP2014523080 A JP 2014523080A JP 2014522868 A JP2014522868 A JP 2014522868A
Authority
JP
Japan
Prior art keywords
protein
preparation
less
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014523080A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014522868A5 (enExample
Inventor
バーンズ，トーマス，エム
ホー，ジンジヤオ
ザービス−パパストートシス，グレゴリー
シヤーマー，エミリー，ベルチヤー
マクニール，ゲイリー，エル
ゴールデン，キヤスリン
Original Assignee
イレブン・バイオセラピユーテイクス・インコーポレイテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イレブン・バイオセラピユーテイクス・インコーポレイテツド filed Critical イレブン・バイオセラピユーテイクス・インコーポレイテツド
Publication of JP2014522868A publication Critical patent/JP2014522868A/ja
Publication of JP2014522868A5 publication Critical patent/JP2014522868A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3847—Multimodal interactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
JP2014523080A 2011-07-29 2012-07-27 精製タンパク質 Pending JP2014522868A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161513453P 2011-07-29 2011-07-29
US61/513,453 2011-07-29
US201261591727P 2012-01-27 2012-01-27
US61/591,727 2012-01-27
PCT/US2012/048631 WO2013019652A1 (en) 2011-07-29 2012-07-27 Purified proteins

Publications (2)

Publication Number Publication Date
JP2014522868A true JP2014522868A (ja) 2014-09-08
JP2014522868A5 JP2014522868A5 (enExample) 2015-09-17

Family

ID=46682907

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014523080A Pending JP2014522868A (ja) 2011-07-29 2012-07-27 精製タンパク質

Country Status (10)

Country Link
US (1) US20140341843A1 (enExample)
EP (1) EP2736524A1 (enExample)
JP (1) JP2014522868A (enExample)
CN (1) CN104066439A (enExample)
AU (1) AU2012290379A1 (enExample)
BR (1) BR112014002173A2 (enExample)
CA (1) CA2843197A1 (enExample)
RU (1) RU2014107743A (enExample)
SG (1) SG10201606218WA (enExample)
WO (1) WO2013019652A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017533194A (ja) * 2014-10-23 2017-11-09 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド ペプチドバリアントを含む医薬組成物及びその使用方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ605928A (en) 2010-07-29 2015-02-27 Eleven Biotherapeutics Inc Chimeric il-1 receptor type i agonists and antagonists
ES2884813T3 (es) * 2013-03-13 2021-12-13 Buzzard Pharmaceuticals AB Formulaciones de citoquina quimérica para administración ocular
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
ES2810813T3 (es) * 2014-01-24 2021-03-09 Am Pharma Bv Procesamiento para recuperación y purificación de una fosfatasa alcalina
TW201538178A (zh) * 2014-03-13 2015-10-16 Eleven Biotherapeutics Inc 生產於吹氣成型充塡密封容器內穩定的嵌合型細胞激素蛋白質配方之方法
TW201702380A (zh) * 2015-02-27 2017-01-16 再生元醫藥公司 宿主細胞蛋白質修飾
CN104710527B (zh) * 2015-02-28 2018-08-24 苏州金盟生物技术有限公司 一种生物制品的内毒素去除方法
KR102617148B1 (ko) * 2016-08-15 2023-12-26 제넨테크, 인크. 비이온성 계면활성제 및 폴리펩티드를 포함하는 조성물에서 비이온성 계면활성제를 정량화하기 위한 크로마토그래피 방법
EP4142792A4 (en) 2020-05-01 2024-11-27 Kashiv Biosciences, LLC An improved process of purification of protein

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4770781A (en) * 1986-03-03 1988-09-13 Merck & Co., Inc. Purification of human interleukin-1 species
JPH02500562A (ja) * 1986-09-04 1990-03-01 イミュネックス・コーポレーション 組み換えインターロイキン‐１の精製
JPH05503007A (ja) * 1989-11-29 1993-05-27 アムジェン　インコーポレーテッド 組み換えヒト・インターロイキン―１インヒビターの生産
JPH0776525A (ja) * 1988-03-09 1995-03-20 Otsuka Pharmaceut Co Ltd インターロイキン−１β組成物の安定化方法
JPH08504755A (ja) * 1992-09-17 1996-05-21 アムジェン ボールダー インコーポレイテッド インターロイキン−１インヒビターの薬学的処方物
JP2000512143A (ja) * 1996-06-07 2000-09-19 グルポ・レペチツト・エス・ピー・エイ 組換え大腸菌からのヒト・インターロイキン１レセプター・拮抗薬の精製方法
JP2006306890A (ja) * 1996-12-06 2006-11-09 Amgen Inc Ｉｌ−１媒介疾患を処置するためにｉｌ−１インヒビターを使用する組合せ療法
US20070082379A1 (en) * 2004-08-25 2007-04-12 Mizhou Hui Novel chimeric polypeptide and use thereof
JP2007531738A (ja) * 2004-04-02 2007-11-08 アムジエン・インコーポレーテツド ＩＬ−１ｒａの凝集を低下させる方法
JP2008521426A (ja) * 2004-12-02 2008-06-26 ドマンティス リミテッド ドメイン抗体への複合体化により血清半減期が延長されたｐｌａｄドメインペプチド
WO2011063195A2 (en) * 2009-11-20 2011-05-26 Dr. Reddy's Laboratories Ltd. Purification of modified cytokines
JP2013535204A (ja) * 2010-07-29 2013-09-12 イレブン・バイオセラピユーテイクス・インコーポレイテツド キメラｉｌ−１受容体１型アゴニストおよびアンタゴニスト

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US5693489A (en) 1984-03-30 1997-12-02 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4883658A (en) 1986-04-28 1989-11-28 Holly Frank J Ophthalmic solution for treatment of dry-eye syndrome
US4804539A (en) 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
US5278151A (en) 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
US5075104A (en) 1989-03-31 1991-12-24 Alcon Laboratories, Inc. Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
ZA912797B (en) 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
AU2002248184C1 (en) 2000-12-12 2018-01-04 Board Of Regents, The University Of Texas System Molecules with extended half-lives, compositions and uses thereof
CN101970678B (zh) 2007-06-21 2014-08-20 慕尼黑科技大学 具有增加的体内和/或体外稳定性的生物学活性蛋白
WO2009023270A2 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
WO2012103240A2 (en) * 2011-01-25 2012-08-02 Eleven Biotherapeutics, Inc. Receptor binding agents

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4770781A (en) * 1986-03-03 1988-09-13 Merck & Co., Inc. Purification of human interleukin-1 species
JPH02500562A (ja) * 1986-09-04 1990-03-01 イミュネックス・コーポレーション 組み換えインターロイキン‐１の精製
JPH0776525A (ja) * 1988-03-09 1995-03-20 Otsuka Pharmaceut Co Ltd インターロイキン−１β組成物の安定化方法
JPH05503007A (ja) * 1989-11-29 1993-05-27 アムジェン　インコーポレーテッド 組み換えヒト・インターロイキン―１インヒビターの生産
JPH08504755A (ja) * 1992-09-17 1996-05-21 アムジェン ボールダー インコーポレイテッド インターロイキン−１インヒビターの薬学的処方物
JP2000512143A (ja) * 1996-06-07 2000-09-19 グルポ・レペチツト・エス・ピー・エイ 組換え大腸菌からのヒト・インターロイキン１レセプター・拮抗薬の精製方法
JP2006306890A (ja) * 1996-12-06 2006-11-09 Amgen Inc Ｉｌ−１媒介疾患を処置するためにｉｌ−１インヒビターを使用する組合せ療法
JP2007531738A (ja) * 2004-04-02 2007-11-08 アムジエン・インコーポレーテツド ＩＬ−１ｒａの凝集を低下させる方法
US20070082379A1 (en) * 2004-08-25 2007-04-12 Mizhou Hui Novel chimeric polypeptide and use thereof
JP2008521426A (ja) * 2004-12-02 2008-06-26 ドマンティス リミテッド ドメイン抗体への複合体化により血清半減期が延長されたｐｌａｄドメインペプチド
WO2011063195A2 (en) * 2009-11-20 2011-05-26 Dr. Reddy's Laboratories Ltd. Purification of modified cytokines
JP2013535204A (ja) * 2010-07-29 2013-09-12 イレブン・バイオセラピユーテイクス・インコーポレイテツド キメラｉｌ−１受容体１型アゴニストおよびアンタゴニスト

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN5014009336; ＥＲＩＣ　Ｓ　ＦＵＲＦＩＮＥ: 'ＥＢＩ-００６：　ＡＮ　ＩＬ-１　ＲＥＣＥＰＴＯＲ　ＩＮＨＩＢＩＴＯＲ　ＤＥＳＩＧＮＥＤ　ＦＯＲ　ＴＨＥ　ＴＲＥＡＴＭＥＮＴ　ＯＦ　ＤＲＹ　ＥＹＥ　ＳＹＮＤＲＯＭＥ' ［ＯＮＬＩＮＥ］ , 20120507, Ｐ１ *
JPN6015030103; Ｃｅｌｌｕｌａｒ　Ｉｍｍｕｎｏｌｏｇｙ Ｖｏｌ．１６９, 1996, ｐ．２２６-２３７ *
JPN6016017049; Ｊ．　Ｂｉｏｌ．　Ｃｈｅｍ． ２８６（４９）（２０１１．１２）, ｐ．４２５９４-６０２ *
JPN6016017056; Ｉｍｍｕｎｏｌｏｇｙ ７７（１９９２）, ｐ．２３５-２４４ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017533194A (ja) * 2014-10-23 2017-11-09 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド ペプチドバリアントを含む医薬組成物及びその使用方法

Also Published As

Publication number Publication date
RU2014107743A (ru) 2015-09-10
BR112014002173A2 (pt) 2017-03-01
AU2012290379A1 (en) 2014-02-06
WO2013019652A1 (en) 2013-02-07
CN104066439A (zh) 2014-09-24
EP2736524A1 (en) 2014-06-04
SG10201606218WA (en) 2016-09-29
CA2843197A1 (en) 2013-02-07
US20140341843A1 (en) 2014-11-20

Similar Documents

Publication Publication Date Title
JP6030554B2 (ja) キメラｉｌ−１受容体１型アゴニストおよびアンタゴニスト
JP2014522868A (ja) 精製タンパク質
WO2012103240A2 (en) Receptor binding agents
TWI691512B (zh) Ｆｃ融合高親和性ＩｇＥ受體α鏈
CN104394881A (zh) 修饰的人肿瘤坏死因子受体-1多肽的新用途
CN114621353B (zh) 一种重组融合蛋白及其应用
TWI586803B (zh) 嵌合介白素-1(il-1)受體型i拮抗劑
HK1181778B (en) Chimeric il-1 receptor type i agonists and antagonists
HK1181778A (en) Chimeric il-1 receptor type i agonists and antagonists

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150727

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150727

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160517

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161220